The FINANCIAL — Boehringer Ingelheim and Eli Lilly and Company on April 19 announced plans to conduct two outcome trials investigating the diabetes medicine Jardiance (empagliflozin) for the treatment ...
RIDGEFIELD, Conn. and INDIANAPOLIS, June 5, 2022 /PRNewswire/ -- Two analyses of the final U.S. data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study show that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback